**Table 2:** Clinical characteristics of individual TN patients.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  **Sex** |  **Age (years)** |  **Side** | **Duration (years)** |  **Pre-op VAS (mm)** |  **Branch** | **SX type**  | **# prev. Medications** **SX** |  |  |  |

***Responders:***

1 M 57.5 R 6 66 3 MVD 0 carbamazepine

2 M 49.0 R 1 100 1/2/3 BC 3 oxcarbazepine, baclofen

3 M 45.1 L 9 98 1 MVD 0 carbamazepine, pregabalin

4 F 58.5 R 11 100 2/3 MVD 0 carbamazepine

5 M 63.9 R 8 82 1/2/3 MVD 0 carbamazepine

6 M 67.5 R 6 71 2/3 BC 0 carbamazepine

7 F 74.1 L 3 81 2 MVD 0 oxcarbazepine, pregabalin

8 F 65 R 1 93 3 MVD 0 gabapentin

9 F 60.3 L 6 36 2/3 MVD 1 gabapentin, amitriptyline

10 F 64.9 L 7 100 2/3 MVD 0 carbamazepine, gabapentin

11 F 60.4 L 7 86 2/3 MVD 0 carbamazepine,

 Oxcarbazepine

12 F 60.4 R 15 80 2/3 BC 0 carbamazepine

13 M 41.8 R 2 89 1/2 MVD 0 carbamazepine, gabapentin, topiramate

14 F 68.5 L 1 100 3 MVD 0 carbamazepine

15 M 61.5 R 2.5 79 3 MVD 0 carbamazepine

16 M 63.3 R 2.5 95 2/3 MVD 0 oxcarbazepine, lamotrigine, gabapentin

17 M 40.6 R 1 15 2/3 BC 0 carbamazepine, baclofen, duloxetine, cannabis oil

***Non-Responders:***

18 F 37.3 L 6 63 2/3 MVD 0oxcarbazepine, baclofen

19 F 48.9 L 8 2 1/2/3 MVD 0 carbamazepine, gabapentin, baclofen

20 F 56.2 R 13 60 1/2/3 BC 1 carbamazepine, gabapentin,

 lamotrigine, baclofen, hydromorphone

21 F 55.5 R 3 100 1/2/3 BC 0 oxcarbazepine, gabapentin

22 F 57.5 R 13 100 1/2/3 BC 2 carbamazepine, gabapentin

23 F 36.3 R 3 89 2/3 MVD 0 carbamazepine, gabapentin, baclofen, amitriptyline, cannabis oil

**M**: male; **F**: female; **VAS**: visual analogue scale; **Branch**: affected trigeminal nerve branches; **SX**: surgical treatment; **MVD**: microvascular decompression; **BC**: balloon compression rhizotomy.